{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,14]],"date-time":"2025-12-14T09:30:54Z","timestamp":1765704654498,"version":"3.48.0"},"reference-count":31,"publisher":"BMJ","issue":"2","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100023331","name":"LEO Pharma A\/S","doi-asserted-by":"crossref","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/501100023331","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2023,1,16]]},"published-print":{"date-parts":[[2023,2]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Safe and effective pharmacological treatment is of paramount importance for treating severe psoriasis. Brodalumab, a monoclonal antibody against interleukin (IL) 17 receptor A, was granted marketing authorisation in the EU in 2017. The European Medicines Agency requested a postauthorisation safety study of brodalumab to address potential safety issues raised during drug development regarding major adverse cardiovascular events, suicidal conduct, cancer and serious infections.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analysis<\/jats:title>\n                    <jats:p>BRodalumab Assessment of Hazards: A Multinational Safety is a multicentre observational safety study of brodalumab running from 2017 to 2029 using population-based healthcare databases from Denmark, Sweden, Norway, Netherlands, Germany and three different centres in Italy. A distributed database network approach is used, such that only aggregate data are exchanged between sites.<\/jats:p>\n                    <jats:p>Two types of designs are used: a case-time-control design to study acute effects of transient treatment and a variation of the new user active comparator design to study the effects of transient or chronic treatment. As comparators, inhibitors of TNF-\u03b1, inhibitors of IL-12 and IL-23, and other inhibitors of cytokine IL-17A are included.<\/jats:p>\n                    <jats:p>In the self-controlled case-time-control design, the risk of developing the outcome of interest during periods of brodalumab use is compared within individuals to the risk in periods without use.<\/jats:p>\n                    <jats:p>In the active comparator cohort design, new users of brodalumab are identified and matched to new users of active comparators. Potential baseline confounders are adjusted for by using propensity score modelling. For outcomes that potentially require large cumulative exposure, an adapted active comparator design has been developed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ethics and dissemination<\/jats:title>\n                    <jats:p>The study is approved by relevant authorities in Denmark, Norway, Sweden, the Netherlands, Germany and Italy in line with the relevant legislation at each site. Data confidentiality is secured by the distributed network approach. Results will be published in peer-reviewed journals.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>EUPAS30280.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2022-066057","type":"journal-article","created":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T11:18:38Z","timestamp":1675250318000},"page":"e066057","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Methodology of the brodalumab assessment of hazards: a multicentre observational safety (BRAHMS) study"],"prefix":"10.1136","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1241-4385","authenticated-orcid":false,"given":"Mette","family":"Reilev","sequence":"first","affiliation":[{"name":"Clinical Pharmacology, Pharmacy and Environmental Medicine, University of Southern Denmark, Odense, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter Bj\u00f8dstrup","family":"Jensen","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology, Pharmacy and Environmental Medicine, University of Southern Denmark, Odense, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6029-2215","authenticated-orcid":false,"given":"Lise Skov","family":"Ranch","sequence":"additional","affiliation":[{"name":"Biostatistics and Pharmacoepidemiology, LEO Pharma A\/S, Ballerup, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8257-1816","authenticated-orcid":false,"given":"Alexander","family":"Egeberg","sequence":"additional","affiliation":[{"name":"Department of dermatology, Copenhagen University Hospital Bispebjerg, Copenhagen, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kari","family":"Furu","sequence":"additional","affiliation":[{"name":"Department of Chronic Diseases, Norwegian Institute of Public Helath, Oslo, Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karin","family":"Gembert","sequence":"additional","affiliation":[{"name":"Department of Medicine Solna, Centre for Pharmacoepidemiology, Karolinska Institute, Stockholm, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Hagg","sequence":"additional","affiliation":[{"name":"Department of Medicine Solna, Centre for Pharmacoepidemiology, Karolinska Institute, Stockholm, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ulrike","family":"Haug","sequence":"additional","affiliation":[{"name":"Clinical Epidemiology, Leibniz-Institute for Prevention Research and Epidemiology-BIPS, Bremen, Germany"},{"name":"Faculty of Human and Health Science, University of Bremen, Bremen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00d8ystein","family":"Karlstad","sequence":"additional","affiliation":[{"name":"Department of Chronic Diseases, Norwegian Institute of Public Helath, Oslo, Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johan","family":"Reutfors","sequence":"additional","affiliation":[{"name":"Department of Medicine Solna, Centre for Pharmacoepidemiology, Karolinska Institute, Stockholm, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8284-448X","authenticated-orcid":false,"given":"Wiebke","family":"Sch\u00e4fer","sequence":"additional","affiliation":[{"name":"Clinical Epidemiology, Leibniz-Institute for Prevention Research and Epidemiology-BIPS, Bremen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarina","family":"Schwartz","sequence":"additional","affiliation":[{"name":"Clinical Epidemiology, Leibniz-Institute for Prevention Research and Epidemiology-BIPS, Bremen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisabeth","family":"Smits","sequence":"additional","affiliation":[{"name":"PHARMO Institute for Drug Outcomes Research, Utrecht, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emily","family":"Holthius","sequence":"additional","affiliation":[{"name":"PHARMO Institute for Drug Outcomes Research, Utrecht, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ron","family":"Herings","sequence":"additional","affiliation":[{"name":"PHARMO Institute for Drug Outcomes Research, Utrecht, The Netherlands"},{"name":"Epidemiology and Data Science, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gianluca","family":"Trifir\u00f2","sequence":"additional","affiliation":[{"name":"Department of Diagnostics and Public Health, University of Verona, Verona, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ursula","family":"Kirchmayer","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, Lazio Regional Health Service, Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandro Cesare","family":"Rosa","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, Lazio Regional Health Service, Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valeria","family":"Belleudi","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, Lazio Regional Health Service, Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6250-877X","authenticated-orcid":false,"given":"Rosa","family":"Gini","sequence":"additional","affiliation":[{"name":"Epidemiology Unit, Agenzia regionale di sanit\u00e0 della Toscana, Florence, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henrik","family":"St\u00f8vring","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology, Pharmacy and Environmental Medicine, University of Southern Denmark, Odense, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jesper","family":"Hallas","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology, Pharmacy and Environmental Medicine, University of Southern Denmark, Odense, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2023,2,1]]},"reference":[{"key":"2025121401271502000_13.2.e066057.1","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1001\/jamadermatol.2021.2007","article-title":"Psoriasis prevalence in adults in the United States","volume":"157","author":"Armstrong","year":"2021","journal-title":"JAMA Dermatol"},{"key":"2025121401271502000_13.2.e066057.2","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.m1590","article-title":"National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study","volume":"369","author":"Parisi","year":"2020","journal-title":"BMJ"},{"key":"2025121401271502000_13.2.e066057.3","doi-asserted-by":"publisher","DOI":"10.3109\/09546634.2013.826341"},{"key":"2025121401271502000_13.2.e066057.4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1503824"},{"key":"2025121401271502000_13.2.e066057.5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1109017"},{"key":"2025121401271502000_13.2.e066057.6","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1111\/bjd.19132","article-title":"Long-term efficacy and safety of brodalumab in psoriasis through 120 weeks and after withdrawal and retreatment: subgroup analysis of a randomized phase III trial (AMAGINE-1)","volume":"183","author":"Papp","year":"2020","journal-title":"Br J Dermatol"},{"key":"2025121401271502000_13.2.e066057.7","doi-asserted-by":"publisher","DOI":"10.1038\/nrd3003"},{"key":"2025121401271502000_13.2.e066057.8","doi-asserted-by":"publisher","DOI":"10.1097\/ACI.0b013e328358cc0b"},{"key":"2025121401271502000_13.2.e066057.9","doi-asserted-by":"crossref","DOI":"10.1111\/dth.12771","article-title":"Psoriasis and suicidality: a review of the literature","volume":"32","author":"Liang","year":"2019","journal-title":"Dermatol Ther"},{"key":"2025121401271502000_13.2.e066057.10","doi-asserted-by":"crossref","first-page":"110347","DOI":"10.1016\/j.jpsychores.2020.110347","article-title":"Suicidal risks with psoriasis and atopic dermatitis: systematic review and meta-analysis","volume":"141","author":"Pompili","year":"2021","journal-title":"J Psychosom Res"},{"key":"2025121401271502000_13.2.e066057.11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2017.08.024"},{"key":"2025121401271502000_13.2.e066057.12","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s00403-016-1712-1","article-title":"Psoriasis and cardiovascular events: updating the evidence","volume":"309","author":"Raaby","year":"2017","journal-title":"Arch Dermatol Res"},{"key":"2025121401271502000_13.2.e066057.13","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s40257-015-0166-0","article-title":"Il-17 blockade in psoriasis: friend or foe in cardiovascular risk?","volume":"17","author":"Torres","year":"2016","journal-title":"Am J Clin Dermatol"},{"key":"2025121401271502000_13.2.e066057.14","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.15830"},{"key":"2025121401271502000_13.2.e066057.15","doi-asserted-by":"publisher","DOI":"10.1097\/00001648-199505000-00010"},{"key":"2025121401271502000_13.2.e066057.16","doi-asserted-by":"publisher","DOI":"10.1007\/s40471-015-0053-5"},{"key":"2025121401271502000_13.2.e066057.17","doi-asserted-by":"publisher","DOI":"10.1002\/pds.5227"},{"key":"2025121401271502000_13.2.e066057.18","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kww079"},{"key":"2025121401271502000_13.2.e066057.19","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1002\/pds.5031","article-title":"Bias in case-crossover studies of medications due to persistent use: a simulation study","volume":"29","author":"Bykov","year":"2020","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2025121401271502000_13.2.e066057.20","unstructured":"Kyntheum - summary of product characteristics. Available: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/kyntheum-epar-product-information_en.pdf [Accessed 29 Mar 2022]."},{"key":"2025121401271502000_13.2.e066057.21","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1007\/s13555-021-00616-7","article-title":"Drug persistence of biologic treatments in psoriasis: a Swedish national population study","volume":"11","author":"Schmitt-Egenolf","year":"2021","journal-title":"Dermatol Ther (Heidelb)"},{"key":"2025121401271502000_13.2.e066057.22","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.11.057"},{"key":"2025121401271502000_13.2.e066057.23","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1002\/pds.4114","article-title":"Determining prescription durations based on the parametric waiting time distribution","volume":"25","author":"St\u00f8vring","year":"2016","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2025121401271502000_13.2.e066057.24","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1097\/EDE.0000000000000001","article-title":"On the validity of the case-time-control design for autocorrelated exposure histories","volume":"25","author":"Jensen","year":"2014","journal-title":"Epidemiology"},{"key":"2025121401271502000_13.2.e066057.25","doi-asserted-by":"publisher","DOI":"10.1111\/joim.12197"},{"key":"2025121401271502000_13.2.e066057.26","unstructured":"1.ENCePPMethodsGuideRev.9.pdf. n.d. Available: https:\/\/www.encepp.eu\/standards_and_guidances\/documents\/1.ENCePPMethodsGuideRev.9.pdf"},{"key":"2025121401271502000_13.2.e066057.27","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0160648","article-title":"Identifying cases of type 2 diabetes in heterogeneous data sources: strategy from the EMIF project","volume":"11","author":"Roberto","year":"2016","journal-title":"PLoS One"},{"key":"2025121401271502000_13.2.e066057.28","doi-asserted-by":"crossref","first-page":"B56","DOI":"10.1016\/j.vaccine.2019.07.045","article-title":"Quantifying outcome misclassification in multi-database studies: the case study of pertussis in the advance project","volume":"38 Suppl 2","author":"Gini","year":"2020","journal-title":"Vaccine"},{"key":"2025121401271502000_13.2.e066057.29","unstructured":"BRAHMS study ENCePP registration. Available: https:\/\/www.encepp.eu\/encepp\/viewResource.htm?id=43504 [Accessed 21 Apr 2022]."},{"key":"2025121401271502000_13.2.e066057.30","doi-asserted-by":"publisher","DOI":"10.1002\/pds.3891"},{"key":"2025121401271502000_13.2.e066057.31","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2020.625755","article-title":"Biologic drug survival in psoriasis: a systematic review & comparative meta-analysis","volume":"7","author":"Mourad","year":"2020","journal-title":"Front Med (Lausanne)"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2022-066057","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,14]],"date-time":"2025-12-14T09:27:23Z","timestamp":1765704443000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2022-066057"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":31,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2023,2,1]]},"published-print":{"date-parts":[[2023,2]]}},"alternative-id":["10.1136\/bmjopen-2022-066057"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2022-066057","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"type":"print","value":"2044-6055"},{"type":"electronic","value":"2044-6055"}],"subject":[],"published":{"date-parts":[[2023,2]]}}}